Gene Mutation Clinical Trials in Nashville, Tennessee

11 recruitingNashville, Tennessee

Showing 111 of 11 trials

Recruiting
Phase 2

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Low-grade NMIBCFGFR Gene AmplificationFGFR Gene Alterations+3 more
Tyra Biosciences, Inc90 enrolled35 locationsNCT06995677
Recruiting
Phase 1

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

OncologyMEK MutationRAF Gene Mutation
Nested Therapeutics, Inc230 enrolled23 locationsNCT06326411
Recruiting
Phase 2

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Intracranial MeningiomaRecurrent MeningiomaNF2 Gene Mutation
Alliance for Clinical Trials in Oncology124 enrolled781 locationsNCT02523014
Recruiting
Phase 1

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

Epidermal Growth Factor ReceptorEpidermal Growth Factor Receptor Gene MutationEpidermal Growth Factor+1 more
EpiBiologics110 enrolled5 locationsNCT07462377
Recruiting
Phase 1

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Acute Myeloid LeukemiaMyeloid SarcomaAcute Myeloid Leukemia, in Relapse+7 more
Kura Oncology, Inc.420 enrolled44 locationsNCT05735184
Recruiting

Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals

Idiopathic Pulmonary Arterial HypertensionHeritable Pulmonary Arterial HypertensionUnaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo+1 more
Vanderbilt University Medical Center150 enrolled1 locationNCT05584722
Recruiting
Phase 1

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

Metastatic MelanomaBRAF Gene Mutation
Rina Plattner30 enrolled4 locationsNCT04903119
Recruiting
Phase 1

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

Solid TumorsMetastatic Hepatocellular CarcinomaAdvanced Solid Tumors+11 more
Tyra Biosciences, Inc100 enrolled16 locationsNCT06915753
Recruiting
Phase 2

Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis

Cystic FibrosisCFTR Gene Mutation
Arcturus Therapeutics, Inc.12 enrolled11 locationsNCT06747858
Recruiting
Phase 1

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

Breast CancerAdvanced CancerAdvanced Solid Tumors+1 more
OnKure, Inc.200 enrolled34 locationsNCT06239467
Recruiting

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

Amyotrophic Lateral SclerosisCorticobasal Degeneration (CBD)Progressive Supranuclear Palsy (PSP)+11 more
Mayo Clinic2,100 enrolled27 locationsNCT04363684